GlobalData on MSN

FDA clears Cepheid’s Xpert GI Panel for pathogen detection

The Xpert GI Panel identifies pathogens directly from stool specimens collected in Cary-Blair transport media.

Cepheid Receives FDA Clearance for Xpert® GI Panel to Support Broad Detection of Gastrointestinal Pathogens

Cepheid announced today that it has received FDA clearance for Xpert GI Panel, a multiplex PCR test designed to provide fast ...
360Dx

Cepheid Enters Rapid Syndromic Testing Space With FDA Clearance of GI Panel

The Danaher subsidiary aims to meet clinician needs for flexibility with a range of test size options for its vast installed base.
Business Wire

Applied BioCode Announces New Nucleic Acid Extraction Claim for KingFisher™ Flex Nucleic Acid Purification System with BioCode® Gastrointestinal Pathogen Panel (GPP)

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode, a leader in molecular diagnostics panel testing, is excited to announce a significant enhancement to its BioCode ® Gastrointestinal Pathogen ...
Business Wire

Applied BioCode to Present Poster at CVS on Multiplex Gastrointestinal Pathogen Detection with a User Friendly, High Throughput Molecular Diagnostic System

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode announced today that its abstract for a poster on “Multiplex Gastrointestinal Pathogen Detection with a User Friendly, High Throughput System ...
JSTOR Daily

Clinical Impact of a Multiplex Gastrointestinal Polymerase Chain Reaction Panel in Patients With Acute Gastroenteritis

Background. Molecular syndromic diagnostic panels can enhance pathogen identification in the approximately 2–4 billion episodes of acute gastroenteritis that occur annually worldwide. However, the ...
Seeking Alpha

University of Pennsylvania’s School of Veterinary Medicine to Evaluate New Gastrointestinal Panel Using LexaGene’s MiQLab System

BEVERLY, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc. (LXXGF), (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative ...